Absci is trading 5.2% down at $7.80 as it extends a sharp selloff from the July 16 session amid broader biotech weakness.
- The move follows a 16.5% drop on July 16, when shares fell from $9.76 to $8.15.
- There is no clear company-specific catalyst for the decline; the move appears driven by a risk-off tone in growth stocks and sector-wide pressure.